BidaskClub Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Buy

BidaskClub cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong-buy rating to a buy rating in a report published on Saturday morning, BidAskClub reports.

Several other equities research analysts also recently issued reports on LMAT. First Analysis upgraded LeMaitre Vascular from a neutral rating to an outperform rating and increased their target price for the stock from $29.00 to $37.00 in a research report on Thursday, July 25th. ValuEngine upgraded LeMaitre Vascular from a hold rating to a buy rating in a research report on Wednesday, September 4th. Barrington Research reiterated an outperform rating and set a $37.00 price objective (up from $32.00) on shares of LeMaitre Vascular in a research note on Thursday, July 25th. Zacks Investment Research raised LeMaitre Vascular from a hold rating to a strong-buy rating and set a $38.00 price objective on the stock in a report on Saturday, July 27th. Finally, Lake Street Capital raised their target price on LeMaitre Vascular from $27.00 to $34.00 and gave the stock a hold rating in a research note on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $35.33.

Shares of LMAT stock opened at $33.38 on Friday. The stock has a market capitalization of $630.14 million, a P/E ratio of 39.74, a PEG ratio of 3.69 and a beta of 1.23. The firm’s 50 day moving average is $31.87 and its 200 day moving average is $29.41. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, July 24th. The medical instruments supplier reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.02. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The company had revenue of $29.48 million during the quarter, compared to the consensus estimate of $28.90 million. During the same period last year, the firm earned $0.43 EPS. LeMaitre Vascular’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, sell-side analysts anticipate that LeMaitre Vascular will post 0.86 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 5th. Investors of record on Wednesday, August 21st were paid a dividend of $0.085 per share. The ex-dividend date was Tuesday, August 20th. This represents a $0.34 annualized dividend and a yield of 1.02%. LeMaitre Vascular’s dividend payout ratio is currently 40.48%.

In related news, Director Lawrence J. Jasinski sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $32.00, for a total transaction of $160,000.00. Following the completion of the transaction, the director now directly owns 10,833 shares in the company, valued at $346,656. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael H. Thomas sold 15,000 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $32.10, for a total value of $481,500.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at $481,500. The disclosure for this sale can be found here. Insiders have sold a total of 98,037 shares of company stock worth $3,310,555 in the last ninety days. 19.60% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the business. Bank of Montreal Can boosted its position in shares of LeMaitre Vascular by 137.6% during the 2nd quarter. Bank of Montreal Can now owns 2,675 shares of the medical instruments supplier’s stock valued at $75,000 after acquiring an additional 1,549 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of LeMaitre Vascular by 66,640.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 3,332 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of LeMaitre Vascular by 22.3% in the second quarter. JPMorgan Chase & Co. now owns 5,215 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 951 shares during the last quarter. Globeflex Capital L P increased its position in shares of LeMaitre Vascular by 26.5% in the first quarter. Globeflex Capital L P now owns 6,578 shares of the medical instruments supplier’s stock worth $204,000 after purchasing an additional 1,378 shares during the last quarter. Finally, BBT Capital Management LLC purchased a new stake in LeMaitre Vascular in the second quarter valued at approximately $234,000. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: What are Closed-End Mutual Funds?

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.